

## Upcoming Medicaid Pharmacy Benefit Change

### Neighborhood News – April 2025

Effective **June 1, 2025**, Neighborhood will update its Medicaid Pharmacy Benefit to remove Stelara from the Medicaid Formulary. Moving forward, we will **exclusively prefer the ustekinumab biosimilars listed below**.

- **Otulfi**
- **Selarsdi**
- **Steqeyma**
- **Yesintek**

**ALL Medicaid adult members currently prescribed Stelara will need to obtain a new prescription for one of the above-listed biosimilars, as existing authorizations for Stelara will be terminated on June 1, 2025.**

For pediatric members:

- Those currently treated with branded Stelara may continue without change
- Pediatric patients new to ustekinumab therapy will be directed to start treatment with a preferred biosimilar if indicated.

Additionally, any member who has been prescribed Stelara in the past 180 days, transitioning to a biosimilar product **will not** require a new authorization within the formulary's allowed quantity limit.

**Otulfi, Selarsdi, Steqeyma, and Yesintek were added to the Medicaid Formulary April 1, 2025, and are available for prescribing immediately to facilitate a smooth transition for our members.**